Imbalance in Protein Thiol Redox Regulation and Cancer-Preventive Efficacy of Selenium

Rayudu Gopalakrishna¹, Usha Gundimeda¹, Sarah Zhou¹, Kristen Zung¹, Kaitlyn Forell¹, and Arne Holmgren²

¹Department of Cell and Neurobiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA; ²Department of Medical Biochemistry and Biophysics, Karolinska Institute, 171 77 Stockholm, Sweden

Correspondence: rgopalak@usc.edu (R.G.)

http://dx.doi.org/10.20455/ros.2016.851
(Received: May 10, 2016; Accepted: May 14, 2016)

ABSTRACT | Although several experimental studies showed cancer-preventive efficacy of supplemental dietary selenium, human clinical trials questioned this efficacy. Identifying its molecular targets and mechanism is important in understanding this discrepancy. Methylselenol, the active metabolite of selenium, reacts with lipid hydroperoxides bound to protein kinase C (PKC) and is oxidized to methylseleninic acid (MSA). This locally generated MSA selectively inactivates PKC by oxidizing its critical cysteine sulfhydryls. The peroxidatic redox cycle occurring in this process may explain how extremely low concentrations of selenium catalytically modify specific membrane-bound proteins compartmentally separated from glutathione and selectively induce cytotoxicity in promoting cells. Mammalian thioredoxin reductase (TR) is itself a selenoenzyme with a catalytic selenocysteine residue. Together with thioredoxin (Trx), it catalyzes reduction of selenite and selenocystine by NADPH generating selenide which in the presence of oxygen redox cycles producing reactive oxygen species. Trx binds with high affinity to PKC and reverses PKC inactivation. Therefore, established tumor cells overexpressing TR and Trx may escape the cancer-preventive actions of selenium. This suggests that in some cases, certain selenoproteins may counteract selenometabolite actions. Lower concentrations of selenium readily inactivate antiapoptotic PKC isoenzymes ε and α which have a cluster of vicinal thiols, thereby inducing apoptosis. Higher concentrations of selenium also inactivate proapoptotic enzymes such as proteolytically activated PKCδ fragment, holo-PKCζ, caspase-3, and c-Jun N-terminal kinase, which all have a limited number of critical cysteine residues and make tumor cells resistant to selenium-induced apoptosis. This may explain the intriguing U-shaped curve that is seen with dietary selenium intake and the extent of cancer prevention.

KEYWORDS | Cancer prevention; Fatty acid hydroperoxides; Protein kinase C; Protein thiol modification; Selenocompounds; Thioredoxin reductase

ABBREVIATIONS | GPX, glutathione peroxidase; GSH, glutathione; MSA, methylseleninic acid; PKC, protein kinase C; p-XSC, 1,4-phenylene-bis(methylene)selenocyanate; ROS, reactive oxygen species; TR, thioredoxin reductase; Trx, thioredoxin
CONTENTS

1. Introduction
2. Complexity in Understanding the Cancer-Preventive Mechanism of Selenium
   2.1. Overview of Important Factors to Be Considered
   2.2. The Promotional Stage of Carcinogenesis Is Suitable for Chemoprevention
   2.3. Efficacy of Various Forms of Selenium for Cancer Prevention and Role of Thioredoxin System
   2.4. Selenium Exerts Its Chemopreventive Actions as Selenoproteins—Antioxidants
   2.5. Selenium Exerts Its Chemopreventive Actions as Selenometabolites—Prooxidants
   2.6. Extremely Low Concentrations of Selenometabolites in Plasma and Tissues
3. PKC Isoenzymes and Their Relevance to Tumor Promotion
   3.1. PKC—a Redox-Sensitive Cysteine-Rich Protein
   3.2. Relevance of PKC Isoenzymes to Apoptosis
4. Hydroperoxide-Mediated Selenium-Induced Inactivation of PKC
   4.1. Tumor Promoter Hydroperoxide-Mediated Redox Cycling of Selenium Inactivates PKC
   4.2. PKC Is a Specific Target to Locally Generated Methylseleninic Acid
   4.3. Differential Sensitivities of PKC Isoenzymes to Redox-Active Selenium
   4.4. Significance of Hydroperoxide-Methylselenol Reaction in Promoting Precancer Cells
   4.5. Selenium “Restores” Cell Death during Tumor Promotion
   4.6. Protein Thiol Oxidation Is Compartmentally Separated from Glutathione
5. Other Protein Thiols Oxidized by Selenium
   5.1. Proteins with Zinc-Thiolates
   5.2. Transcriptional Factors
   5.3. Apoptosis-Related Proteins
6. Relationship between Selenoproteins and Selenometabolites
   6.1. Selenoproteins Antagonize Selenometabolite Actions—Resistance to Selenium
   6.2. Selenoproteins Support Selenometabolite-Induced Cell Death
7. U-Shaped Curve in Selenium-Induced Cancer Prevention
8. Conclusions and Perspectives

1. INTRODUCTION

Several epidemiologic studies showed an inverse relationship between the status of dietary selenium intake and the risk of cancer at various sites in humans [1]. However, a small number of epidemiologic studies did not find such an association [2, 3]. Numerous experimental studies of carcinogenesis in rodent models showed that supplementation using certain forms of selenium at doses (1 to 3 ppm) well above the nutritional requirement (0.1 ppm) decreased tumorigenesis in various organs [4–6]. Nevertheless, some studies did not find this effectiveness of selenium, and a limited number of studies even showed an increase in tumorigenesis with selenium supplementation [7, 8]. Early clinical trials in China showed that selenium was moderately effective in preventing both liver and esophageal cancers in humans [9]. Additionally, the Nutritional Prevention of Cancer (NPC) trial conducted by Clark et al in the United States suggested that supplemental selenium in the form of selenized yeast may reduce the incidence and mortality of cancers of the prostate, lung, and colon-rectum, but not cancers of the breast and skin [10]. However, the Selenium and Vitamin E Cancer Prevention trial (SELECT), a large-scale clinical trial employing selenomethionine, did not show any efficacy of selenium in preventing prostate cancer [11]. SELECT also showed a nonsignificant increase in diabetes with selenium supplementation [11]. Furthermore, additional clinical trials conducted with selenized yeast did not show efficacy of selenium in the prevention of cancer at various sites in the body [12]. Conceivably, the studies carried out over the past four to five decades support the notion that selenium supplementation may decrease the incidence of cancer in some cases, fail to do so in other cases, or may even cause unwanted effects and toxicity [12].
Although the form of selenium used in prevention studies may be an important factor in explaining some of the aforementioned discrepancies, understanding the cancer-preventive mechanism of selenium may shed light on why it works in some cases and fails in others. Selenium is a transition metal and its redox chemistry plays an important role in its actions in basic nutrition, cancer prevention, and toxicity. The ability of selenium to induce oxidation of protein thiols has been known for some time [13]. Protein thiol oxidation is emerging as an important mechanism in regulating key signaling enzymes such as protein kinase C (PKC), protein tyrosine phosphatases, and various transcriptional factors which influence tumorigenesis and cell death [14–16]. Therefore, this may be an important redox regulatory mechanism we can study to understand conflicting observations of the efficacy of selenium and to optimize its efficacy as a cancer-preventive agent.

The purpose of this review is to discuss the current state of knowledge regarding redox regulation of protein thiol homeostasis in order to illustrate how selenium selectively kills precancer cells, how tumor cells escape from it, and why a U-shaped curve is seen with dietary selenium intake and the extent of cancer prevention. We will use PKC isoenzymes and various other proteins as examples to illustrate selenium-induced protein thiol oxidations.

2. COMPLEXITY IN UNDERSTANDING THE CANCER-PREVENTIVE MECHANISM OF SELENIUM

2.1. Overview of Important Factors to Be Considered

In proposing a cancer-preventive mechanism for selenium, all the following important criteria must be taken into account: (1) the mechanism should consider the susceptibility of the promotional stage of carcinogenesis to selenium action as well as the efficacy of various forms of selenium for cancer prevention; (2) it should also clarify the relative role of selenoproteins and low-molecular weight selenometabolites, which are present at very low levels in tissues; (3) it should have specific and sensitive target(s) for selenium relevant to cell signaling in the events related to tumor promotion; (4) the proposed mechanism should address how key protein targets are oxidatively modified by selenium in the cell where millimolar concentrations of antioxidant thiol glutathione (GSH) are present; (5) it should explain how selenium induces selective toxicity in precancer cells but not in normal cells; (6) the mechanism should clarify how tumor cells can escape from selenium, leading to failure of chemoprevention; and finally, (7) the proposed mechanism should clarify why a U-shaped curve is seen when measuring the extent of cancer prevention with increasing selenium intake. In this review, we have addressed all these issues while discussing redox mechanisms that perturb protein thiol homeostasis in order to explain the success and failure of selenium as a cancer-preventive agent.

2.2. The Promotional Stage of Carcinogenesis Is Suitable for Chemoprevention

Selenium exerts its preventive effects at the initiation phase of tumorigenesis by inhibiting carcinogen binding to DNA [17]. In addition, selenium inhibits tumor promotion and angiogenesis as well as stimulates the immune system [18]. In cell culture experiments, a lower concentration of selenium is required for the inhibition of promotion of precancer cells than for the inhibition of growth of advanced malignant cells [19, 20]. Furthermore, there is limited evidence to support that dietary selenium at a level nontoxic to the host can prevent the growth of transplanted tumors in animals [21]. In vitro, higher doses of selenium induce apoptosis of advanced malignant cells [22]. These growth-inhibiting and apoptosis-inducing mechanisms may be important in the promotion stage of carcinogenesis, in which there is a clonal expansion of preneoplastic cells that escape death. The high incidence of prostate cancer and the decades of preneoplasia during its development make this cancer well-suited for chemoprevention trials. Although various stages of carcinogenesis are susceptible to the cancer-preventive actions of selenium, the promotion stage, with its longer duration, is most ideal.

2.3. Efficacy of Various Forms of Selenium for Cancer Prevention and Role of Thioredoxin System

The cancer-preventive efficacy of selenium varies depending on its chemical form [23, 24]. Naturally occurring organic forms of selenium, such as Se-
methylselenocysteine, is efficacious in preventing cancer and is less toxic [25]. Although inorganic selenite has cancer-preventive potential, it is too toxic. The reason for its toxicity is the direct reaction with the thioredoxin system leading to redox cycling and production of reactive oxygen species (ROS) [26, 27]. Thioredoxin system comprising NADPH, thioroxygen reductase (TR) and thioredoxin (Trx) is present in all cells from bacteria to man and was originally discovered as the hydrogen donor for ribonucleotide reduction in E.coli [28, 29]. Each deoxynucleotide formed from the corresponding ribonucleotide gives rise to a disulfide in the enzyme which has to be reduced [30]. The thioredoxin system is now known to be a general disulfide reduction system and via peroxiredoxins control the level of hydrogen peroxide (H₂O₂) in cells [29]. Purification and characterization of the thioredoxin system from rat liver demonstrated that the TR enzyme was larger and had a broad substrate specificity compared to the smaller specific bacterial enzyme [31]. Substrates remarkably included selenite and selenodiglutathione which were shown to be direct substrates for the TR enzyme but also fast oxidants of reduced Trx [26, 27]. Of particular interest was that selenite in the presence of NADPH and TR resulted in a large non-stochiometric oxidation of NADPH in the presence of oxygen. This result showed two important facts. First, TR and Trx play a major role in generating the selenide for the cotranslational synthesis of the 25 selenoproteins in human genome. Second, it may help to explain why there is no free pool of selenocysteine since it will also redox cycle with NADPH and TR in the presence of oxygen [32]. Remarkably, these results were published before it was known that mammalian TR itself is a selenoprotein. This included the result showing that the human TR enzyme reduced lipid hydroperoxides directly by NADPH and free selenocysteine strongly stimulated the reaction due to catalytically generated selenols [33]. Furthermore, it was discovered that dinitrochlorobenzene was an irreversible inhibitor of the enzyme where loss of thioroxygen reductase activity was accompanied by a large increase in NADPH oxidase activity (30-fold) [34]. The mechanism of this was later shown to involve modification of the selenocysteine in the active site [35] following the discovery that the enzyme is a selenoenzyme [36, 37] with a selenenylsulfide active site in the C-terminus and a selenolthiol being the catalytic active site. There are three genes for TR in mammalian cells with TR2 and Trx2 in mitochondria and TR1 and Trx1 in the cytosol/nucleus, respectively [30, 38]. Recent results have highlighted the role of the GSH/glutaredoxin and TR systems in carcinogenesis [39].

Selenomethionine is the major form of selenium in typical diets [40]. However, it rapidly incorporates into proteins, whereas Se-methylselenocysteine does not. Some clinical trials such as NPC used selenized yeast, which contains high amounts of selenomethionine and significant amounts of several other forms of selenium [10]. Since there is a batch-to-batch variation in the composition of selenized yeast, selenomethionine, which is considered to be the major form of selenium in the selenized yeast, was chosen for SELECT [41]. Given that selenomethionine did not prevent tumorigenesis in various animal models, some speculated that selenomethionine is not an appropriate form to use for cancer prevention clinical trials [42, 43]. Selenomethionine can inhibit tumor
cell growth and induce apoptosis in vitro, but requires high (micromolar) concentrations [44], which is likely due to the limited metabolism of this parent compound in culture. Synthetic methylseleninic acid (MSA), a second generation cancer-preventive selenocompound, is more effective than naturally occurring selenomethionine in both in vitro and in vivo models of cancer prevention [43, 45]. MSA is a stable oxidation product of volatile methylselenol, a presumed cancer-preventive metabolite of selenium [23]. Certain synthetic selenocompounds, such as 1,4-phenylene-bis(methylene)selenocyanate (p-XSC) were also shown to be more effective than selenomethionine in preventing carcinogenesis in rodent models [6, 42]. Why certain forms of selenium are more effective than others is not clearly understood.

2.4. Selenium Exerts Its Chemopreventive Actions as Selenoproteins—Antioxidants

At a nutritional level (0.1 ppm), selenium is essential to selenoprotein glutathione peroxidase (GPX), which protects cells from H2O2 and organic peroxides [46]. However, the amount of selenium required for cancer prevention (1 to 3 ppm) is well above levels required for optimal expression of GPX activity. This suggests involvement of additional mechanisms in the cancer-preventive actions of selenium.

Unlike other selenoproteins previously characterized, TR was observed to have a two-fold increase in activity upon dietary supplementation with selenite [47, 48]. However, this has not been observed with supplementation of other forms of selenium [49]. The expression of both Trx and TR was found to be increased several fold in some tumors compared to normal tissues [36, 50]. Overexpression of Trx inhibits apoptosis [51]. Given the importance of oxidative stress in tumor promotion, the antioxidant functions of GPX and TR are very relevant to the cancer-preventive actions of selenium. Nevertheless, their precise role is unknown.

2.5. Selenium Exerts Its Chemopreventive Actions as Selenometabolites—Prooxidants

Selenocompounds, such as selenite, selenomethionine, and Se-methylselenocysteine eventually generate selenide [23] which is ultimately incorporated into selenoproteins [46] (Figure 1). When selenide is generated in large amounts, it also reacts with oxy-

![FIGURE 2. Cysteine-rich regions present in PKC isoenzymes. Unique structural aspects of PKC make it a receptor for not only tumor promoters but also anti-tumor promoters. C1: cysteine-rich constant region present in various PKC isoenzymes. C1A: first two zinc-thiolates in the C1 domain; C1B: second two zinc-thiolates in the C1 domain; C2: Ca\(^{2+}\)-binding domain present in only conventional PKC isoenzymes (\(\alpha\), \(\beta\), and \(\gamma\)), but absent in novel PKC isoenzymes (\(\delta\), \(\varepsilon\), \(\eta\), and \(\theta\)) and atypical PKC isoenzymes (\(\zeta\), \(\iota\), and \(\lambda\)); C3: ATP-binding region in the catalytic domain; C4: protein substrate-binding region in the catalytic domain; V3: proteolysis susceptible variable region present in various PKC isoenzymes; pseudosubstrate: autoinhibitory region prevents the binding of protein substrate to the catalytic domain.](image_url)
2.6. Extremely Low Concentrations of Selenometabolites in Plasma and Tissues

At cancer-preventive doses, the total concentration of selenium is considered to be approximately 10 μM. Most (> 90%) selenium in the blood is bound to proteins or is present as selenoproteins [55], and only a limited amount (< 5%) is present as selenometabolites. This is important as it minimizes the occurrence of global toxicity of selenium. However, this raises an important challenge in understanding how such low tissue-available concentrations (nM) of selenometabolites can exert their cancer-preventive actions [56]. At the nutritionally adequate low dose (0.1 ppm), selenium’s actions are believed to be mediated primarily by selenoproteins, while at the toxic high dose (> 5 ppm), its actions are believed to be mediated by selenometabolites [1]. However, at the cancer-preventive intermediate doses (1 to 3 ppm), whether selenium exerts its actions exclusively as selenometabolites or through a combination of selenometabolites and selenoproteins is not known. Since selenium is a redox catalyst and protein thiols are very sensitive targets for redox modifications, proteins having clusters of cysteine residues are the most relevant targets for selenometabolites.

3. PKC ISOENZYMES AND THEIR RELEVANCE TO TUMOR PROMOTION

3.1. PKC—a Redox-Sensitive Cysteine-Rich Protein

PKC, a family of isoenzymes, is activated not only by lipid second messengers [57] but also by tumor promoters such as phorbol esters, oxidants, and fatty acid hydroperoxides [58–63]. A four-fold increase in the generation of diacylglycerol in prostate cancer tissue compared to benign tissue suggests a role for PKC in prostate tumorigenesis [64]. PKC has unique structural aspects that render it susceptible to activation by oxidants such as H$_2$O$_2$, periodate, and tobacco tumor promoters [14, 58–60].

There are two types of cysteine-rich regions present in PKC isoenzymes: one in the regulatory domain and the other in the catalytic domain (Figure 2). The cysteine-rich region present in the regulatory domain coordinates the binding of four zinc atoms [65]. Selective modification of these zinc-thiolates by tumor-promoting peroxides leads to collapse of the autoinhibitory region in the regulatory domain and cofactor-independent activation of PKC [14]. In contrast, modification of cysteine residues within the catalytic domain of the enzyme by alkylating agents and oxidants at high concentrations results in inactivation of PKC [66].

![FIGURE 3. Selenium-induced inactivation of PKC induces apoptosis—opposing roles of PKC isoenzymes.](image-url)
FIGURE 4. Hydroperoxide-mediated methylselenol-MSA redox cycle inactivates PKC. Initially, methylselenol generated by the TR system reduces lipid hydroperoxides bound to PKC and it, in turn, is oxidized to MSA. This locally generated MSA oxidizes PKC cysteine sulfhydryls present within the vicinity and inactivates the kinase. This reaction regenerates methylselenol, which reacts with another molecule of lipid hydroperoxide. The methylselenol-MSA redox cycle makes low concentrations of selenium to catalytically oxidize protein sulfhydryls. TRX binds with a high affinity to the PKC catalytic domain. Therefore, the TR system efficiently reduces disulfides formed within the PKC catalytic domain and regenerates its lost kinase activity.

3.2. Relevance of PKC Isoenzymes to Apoptosis

A variety of agents that induce PKC inactivation induce apoptosis [67, 68] (Figure 3). The inactivation of PKC activates sphingomyelinase to increase the generation of ceramide [69–71]. Although apoptosis can be prevented by Bcl-2 [72], its anti-apoptotic function is compromised when Bcl-2 is not phosphorylated by PKCα and downstream ERK [73]. The ceramide-induced changes in mitochondria trigger the release of cytochrome c into cytosol where it induces the activation of caspase-3, a key protease involved in the initiation of apoptotic events [74, 75].

Various PKC isoenzymes respond differently to stimuli that cause tumor promotion, cell growth, and cell death [76]. The role of PKCα in cell growth and cell death varies depending on cell type [77]. PKCε has oncogenic potential and is a promitogenic and prosurvival enzyme [76]. PKCε expression significantly increases in prostate cancer in a manner correlating with the aggressiveness of the disease [78]. Unlike PKCε, PKCδ is a proapoptotic and antitumorigenic isoenzyme. A limited proteolysis of PKCδ at its hinge region by caspase-3 separates its autoinhibitory regulatory domain from the catalytic domain [76]. This cofactor-independent, constitutively active catalytic fragment of PKCδ mediates an important role in executing apoptosis. PKCζ that is activated by ceramide also plays a role in inducing apoptosis [79]. Therefore, it is important to know whether selenium differentially inactivates antiapoptotic and proapoptotic PKC isoenzymes causing either tumor cell death or survival.

4. HYDROPEROXIDE-MEDIATED SELENIUM-INDUCED INACTIVATION OF PKC

4.1. Tumor Promoter Lipid Hydroperoxide-Mediated Redox Cycling of Selenium Inactivates PKC

Fatty acid hydroperoxides reversibly activate PKC isoenzymes [63]. Direct reactivity of the lipid hydroperoxides with sulfhydryls is very low; therefore, it will not directly oxidize cysteine residues. However, methylselenol reacts with the lipid hydroperoxides that are bound to PKC and reduces them, and in turn, methylselenol is oxidized to MSA (Figure 4). This locally generated MSA specifically oxidizes PKC cysteine sulfhydryl residues present within the vicinity [80]. Given that a cluster of cysteine residues present within the PKC catalytic domain does not coordinate binding of metal ions, MSA readily oxidizes these cysteine residues and inactivates the enzyme. During this process, at least two disulfide bonds are formed in the calcium-dependent classic PKC isoenzymes (α, β, and γ). Although the PKC regulatory domain also has a cluster of 12 cysteine residues, they coordinate binding of four zinc ions. This makes them less susceptible to oxidation induced by MSA. However, if MSA is formed in high amounts, it can also oxidize the zinc-thiolates present within the regulatory domain [80]. In these oxidative reactions, MSA is reduced back to methylselenol, which repeats the reduction of fatty acid hydroperoxides. The methylselenol-MSA redox cycle allows selenium to catalytically oxidize many sulfhydryls in PKC even at low nanomolar concentrations. It is in-
triguing that what is a receptor for various tumor promoters is also a critical target for cancer prevention. As a result, selenium may effectively halt tumor promotion.

4.2. PKC Is a Specific Target to Locally Generated Methylseleninic Acid

A complete reduction of MSA to methylselenol requires four thiols. It involves an addition reaction and intermediate formation of selenosulfide: \( \text{CH}_3\text{SeO}_2\text{H} + 4 \text{RSH} \rightarrow \text{CH}_3\text{SeH} + 2 \text{RSSR} + 2 \text{H}_2\text{O} \). Thus, two pairs of juxtaposed sulfhydryls may be more effectively oxidized than one cysteine residue or two vicinal cysteine residues present in proteins. It is important to note that if MSA is formed distant from PKC in the cell its reactivity with PKC will be lower and less specific. Therefore, a local generation of MSA and redox cycle of methylselenol-MSA within the vicinity of PKC occurring with the membrane lipid hydroperoxides makes PKC a sensitive and specific target for selenium in the cell membrane compartment.

4.3. Differential Sensitivities of PKC Isoenzymes to Redox-Active Selenium

Among PKC isoenzymes, the conventional isoenzymes \( \alpha, \beta, \) and \( \gamma \) are more sensitive to both MSA and selenite than the novel isoenzymes \( \varepsilon \) and \( \delta \), whereas atypical isoenzyme \( \zeta \) is the least sensitive among PKC isoenzymes tested [80, 81]. This is consistent with the lower number of conserved cysteine residues present in the catalytic domain of PKC\( \zeta \) compared to that of other PKC isoenzymes. Our previous studies suggested that the PKC\( \alpha \) inhibition alone is not sufficient for MSA-induced apoptosis and that inactivation of PKC\( \varepsilon \) is required as well [80]. Inactivation of PKC\( \varepsilon \), an oncogenic, promitogenic, and prosurvival enzyme, by selenium decreases cell proliferation and induces apoptosis. This hypothesis is further supported by the fact that the prostate cancer cells or premalignant cells overexpressing PKC\( \varepsilon \) become less sensitive to MSA. Conversely, knockout of PKC\( \varepsilon \) expression makes these cells more sensitive to MSA. PKC\( \delta \) is also inactivated by MSA at a rate equal to that of PKC\( \varepsilon \). Since methylselenol-MSA redox cycles occur with the hydroperoxide bound to the regulatory domain, it is more likely that the caspase-3-mediated proteolytic separation of the PKC\( \delta \) regulatory domain from the catalytic domain makes the latter domain less susceptible to inactivation by the methylselenol-MSA redox cycle. Thus, it is possible that at low concentrations, this redox cycle selectively inactivates cell survival isoenzymes such as PKC\( \varepsilon \) and spares the activity of proteolytically activated catalytic fragment of PKC\( \delta \) and holo-PKC\( \zeta \), which are needed for executing apoptosis.

4.4. Significance of Hydroperoxide-Methylselenol Reaction in Promoting Precancer Cells

Fatty acid hydroperoxides have been implicated in tumor promotion in various sites including the prostate [14]. Such hydroperoxides may be generated by the overexpression of lipoxygenases and nonenzymatic oxidation of unsaturated fatty acids by oxidative stress and inflammation associated with tumor promotion [82, 83]. In promoting precancer cells where fatty acid hydroperoxides or other oxidants are in high concentrations, volatile methylselenol is retained after conversion to nonvolatile MSA, causing selective toxicity to these cells. It is intriguing that fatty acid hydroperoxides and other oxidants that induce tumor promotion may also help in mediating the chemopreventive actions of selenium. In contrast, in the normal cells where lipid hydroperoxides or oxidants are very low, volatile methylselenol is oxidized to nonvolatile MSA and thus leaves normal cells or gets converted to excretory metabolites. Thus, methylselenol is less toxic to normal cells.

4.5. Selenium “Restores” Cell Death during Tumor Promotion

Oxidant tumor promoters are capable of inducing cell death in normal cells. However, some premalignant or malignant cells escape oxidant-induced cell death and accumulate mutations induced by oxidants, which ultimately lead to tumor promotion and progression [84]. Low concentrations of selenol, retained and amplified by peroxides, block tumor cells from escaping death and “restore” apoptosis. The concept of selenium “restoring” cell death is different from selenium per se inducing cell death. Selenium per se induces cell death only at high concentrations by a global toxic mechanism. With a direct selenium cytotoxicity approach (global toxici-
4.6. Protein Thiol Oxidation Is Compartmentally Separated from GSH

Although several cases of protein thiol oxidation by selenium or oxidants have been demonstrated, it is often not addressed how protein thiol oxidation occurs in the reducing environment of the cell where there are millimolar concentrations of GSH, a thiol antioxidant present in the cytoplasm. PKC translocates from the cytoplasm to the cell membrane in cells treated with various tumor promoters [85]. A cellular depletion of GSH did not enhance inactivation of PKC by selenocompounds [20]. Since fatty acid hydroperoxides are abundant in the cell membrane, which is subjected to oxidative stress, the peroxidative redox cycle of methylselenol-MSA oxidizes thiol-rich regions in the membrane-bound proteins compartmentally separated from GSH.

5. OTHER PROTEIN THIOLS OXIDIZED BY SELENIUM

5.1. Proteins with Zinc-Thiolates

In metallothioneins, each zinc atom is bound tetrahedrally to four cysteine residues to form extensive zinc-thiolate cluster networks between 7 zinc atoms and 20 cysteine thiolates [86]. Redox-active selenocompounds oxidize these zinc-thiolate clusters with low redox potential and release the bound zinc from metallothioneins [86]. Enzymes involved in DNA repair, such as formimidopyrimidine-DNA glycosylase and xeroderma pigmentosum group A protein, have zinc thiolates and as such, various reducible selenocompounds oxidize these thiolates and release zinc from the enzymes, causing the collapse of their DNA-binding sites [87]. Estrogen receptor-beta also has two zinc-thiolate clusters in the DNA-binding domain. However, MSA treatment of prostate cancer cells did not affect the receptor binding to estrogen response element or the estrogen-regulated gene expression [88]. As mentioned before, the zinc-thiolates in PKC are oxidized to a lesser extent than the free thiolates present within the catalytic domain which are not coordinating zinc [80, 81]. Overall, the rate of the selenium-induced oxidation of thiolates depends on their redox potential, which is in turn influenced by adjacent amino acid residues in the protein. Therefore, zinc-thiolates in different proteins may have different degree of susceptibility to selenium-induced oxidation. Since sulphydryl oxidation by redox-active selenocompounds involves initial addition reaction and formation of selenosulfide, it is possible that the binding of redox-inert zinc to thiolates makes them oxidized at a lower rate than free...
thiolates. However, further studies are needed to address this issue.

5.2. Transcriptional Factors

A decrease in transcriptional factor AP-1 binding to DNA was observed in selenite and selenodiglutathione-treated cells [89]. The authors have suggested that cysteine-modification in TRX contributes to a decrease in Ref-1 activity, which is required for activation of Jun and Fos proteins. In addition, MSA has been shown to inhibit the binding of transcriptional factor NF-κB to DNA and the expression of antiapoptotic genes in the prostate cancer cells [90]. Furthermore, MSA significantly downregulated Keap1, thereby inducing the activation of Nrf2 and antioxidant response element (ARE) promoter activity in esophageal squamous cell carcinoma cells [91]. The authors suggested that the downregulation of Keap1 occurred by MSA-induced miR-200a expression. However, no experiments were carried out in this study to determine whether MSA indeed induced a redox modification of two vicinal cysteines in Keap1, which are highly susceptible to oxidation and addition reactions [92]. Another organic selenocompound, ebselen, has been shown to induce redox modification of cysteine 151 in Keap1 and liberation and activation of Nrf2 [93]. Both selenocompounds selenite and p-XSC decreased the binding of transcription factors Sp1 and Sp3 to their consensus site in DNA [94]. In addition, some authors have shown activation of p53, a tumor suppressor protein, by selenomethionine in lung cancer cells [95]. In this process, a reduction of its two cysteine residues that require Ref-1 was observed. The authors suggested the significance of this selenum-dependent activation of p53 on DNA repair in cancer prevention.

5.3. Apoptosis-Related Proteins

Selenite can activate apoptotic machinery through redox-dependent activation of Bax, a Bcl-2 family protein, by modifying two conserved cysteine residues present in this protein [96]. On the contrary, selenite inactivates proapoptotic protease caspase-3 in HEK293 cells [97]. Indeed, selenite directly inactivates recombinant caspase-3 by inducing reversible thiol redox modification of critical cysteine residue present within the active site. In cells, selenite also inactivates enzymes such as c-Jun N-terminal kinase and p38, which are involved in inducing cell death in response to external stresses [98]. Selenite directly inactivates c-Jun N-terminal kinase by a direct modification of a single cysteine residue. However, the inactivation of p38 is caused by the effect of selenite on target(s) upstream to p38 rather than by the direct modification of the enzyme [98].

6. RELATIONSHIP BETWEEN SELENOPROTEINS AND SELENOMETABOLITES

6.1. Selenoproteins Antagonize Selenometabolite Actions—Resistance to Selenium

In studies carried out with intact tumor cells or purified PKC isoenzymes, the TR system reduced the selenium-induced disulfides in PKC regenerating its lost kinase activity [80]. It is intriguing that selenometabolite action on PKC is nullified by selenoprotein TR. It is also interesting to note that TRX or related proteins bind with high affinity to the PKC catalytic domain [99]. Inhibition of TR activity by its specific inhibitor auranofin was shown to increase MSA-induced inactivation of PKC in cells [80]. Therefore, in cells treated with methylselenol or MSA, TR is a limiting factor for the reduction of oxidized sulphydryls in PKC to regenerate its kinase activity.

An opposing relationship may exist between the actions of selenometabolites and selenoproteins. It is important to elucidate this relationship in order to clarify the complexity of selenium as a pro-oxidant and an antioxidant. Selenometabolites, as pro-oxidants, generate free radicals and cause lipid peroxidation and DNA damage [100]. Selenoproteins, as antioxidants, negate the actions of selenometabolites. For example, selenometabolites such as selenite produce H₂O₂ and result in the formation of lipid hydroperoxides [101], which are removed by selenoprotein GPX. Similarly, selenometabolite-induced protein thiol oxidation is reversed by the TR system as seen in the PKC model discussed above. Furthermore, TR converts protein sulphydryl-oxidizing MSA into volatile methylselenol, which cannot directly oxidize protein thiols. In addition, removal of fatty acid hydroperoxides by GPX-4 could take away the hydroperoxides necessary for the conversion of methylselenol to MSA.
The opposing relationship between selenometabolites and selenoproteins may provide an interesting scenario to explain why cancer preventive concentrations of selenium are safe to normal cells while being selectively cytotoxic to precancer cells but not to advanced malignant cells (Figure 5). Since volatile selenometabolites are retained to a lesser extent in normal cells due to presence of low amounts of lipid hydroperoxides, selenometabolite toxicity is low and selenoproteins can effectively safeguard against this toxicity. On the contrary, in precancer promoting cells, due to presence of high amounts of lipid peroxides, selenometabolites are retained to a greater extent and cause greater toxicity. This overpowers selenoproteins, leading to selective selenium toxicity to precancer cells. An increased expression of TR was observed in many tumors compared to their normal counterparts [36, 50]. Various skin tumor promoters have been shown to increase the expression of TR and TRX [102]. This can cause escape of tumor cells from selenium-induced cell death, leading to failure of chemoprevention by selenium.

6.2. Selenoproteins Support Selenometabolite-Induced Cell Death

In some conditions, selenoproteins may support selenometabolite actions. For example, high amounts of TR may increase selenite conversion to selenide, which then undergoes the redox cycle, induces oxidative stress, inhibits lipoxygenases, and induces apoptosis [103, 104]. There are also suggestions that in some cases, TR can function as a cell death-inducing enzyme instead of a cell survival enzyme [105]. Paradoxical roles of TR and GPX in cellular survival [106] further complicate understanding their role in selenium-induced cancer prevention. Conceivably, knowledge of this complex relationship between selenometabolites and selenoproteins may help further understanding of why certain cancers are prevented by selenium and others are not.

7. U-SHAPED CURVE IN SELENIUM-INDUCED CANCER PREVENTION

An intriguing U-shaped dose-response relationship was observed between dietary selenium intake and the extent of DNA damage in the canine prostate [107]. In the NPC trial, the initial selenium status of the people was found to be an important determining factor for the efficacy of cancer prevention by selenium [10]. Selenium supplementation was found to decrease cancer incidence in men with baseline plasma selenium levels that fell in the lowest two tertiles (< 122 ng/mL). In contrast, those in the highest tertile showed an increase in cancer incidence. Similarly, in the Southwest Oncology Group S9917 high-grade prostatic intraepithelial neoplasia trial, selenomethionine supplementation (200 µg/day) reduced prostate cancer risk in men with the baseline plasma selenium level in the lowest quartile (<106 ng/mL) [108]. In our studies, we found a biphasic effect of MSA on growth inhibition and induction of cell death in a human prostate cancer cell line (WPE1-NB26); lower concentrations of MSA induced cell
growth inhibition and cell death whereas higher concentrations of MSA did not (unpublished results).

The observed biphasic effect of MSA may be due to a variation in sensitivity of proteins to redox-active selenium and their differences in subcellular localization (Figure 6). More sensitive protein targets having a cluster of vicinal thiols and the ability to bind membrane hydroperoxides are inactivated by low concentrations of selenium that undergoing catalytic redox cycle compartmentally separated from GSH [20, 80]. These targets include enzymes such as PKC (α and ε isoenzymes), whose inactivation may induce apoptosis [80]. On the other hand, low affinity targets that have limited cysteine residues or are located in the cytoplasmic compartment, such as caspase-3, PKCζ, and proteolytically activated PKCδ, are not affected by low concentrations of selenium. Therefore, the apoptotic process is executed in the cell by low concentrations of MSA [80]. With an increase in MSA concentration, it is possible that these low affinity proapoptotic targets are also inactivated by MSA, and as such, it fails to induce apoptosis. Similarly, modification of one or two cysteine residues in Keap1 may be expected to occur only at higher concentrations of MSA, leading to the activation of Nrf2. The activation of Nrf2 is subsequently results in induction of antioxidant/cytoprotective enzymes, including the selenoproteins TR and GPX [92]. This may protect cells from MSA-induced cell death. Although various studies identified protein thiol targets for different redox-active selenocompounds in different cell systems, studies assessing the relative sensitivity of various targets to a given selenocompound in the same cell type are needed to understand further this biphasic effect of selenium in cancer prevention.

**8. CONCLUSIONS AND PERSPECTIVES**

Given the ability of redox-active selenocompounds to induce protein thiol oxidation, understanding redox regulation of critical cellular proteins which influence cell death and survival is important to elucidate why selenium prevents cancer in some cases only. PKC isoenzymes are well-qualified targets for protein thiol regulation in cancer-preventive actions of selenium. Several other proteins with critical cysteine residues are also oxidatively modified by selenium. However, additional critical studies are needed to address the significance of such modifications in cancer prevention.

In this review, we considered various criteria necessary to propose a cancer-preventive mechanism for selenium. First, we address how the promotional stage of carcinogenesis, with its long duration, is well suited for chemoprevention. PKC isoenzymes are targets for both endogenous and exogenous tumor promoters. Therefore, as a receptor for tumor promoters, PKC is a well-qualified target for preventing tumor promotion. At the same time, it has unique structural features that render it susceptible to selenium-induced thiol-redox regulation. The intriguing aspect is that selenium uses the same receptor to which tumor promoters bind and thus effectively block the tumor promotion process. Second, methylselenol and other selenol metabolites of synthetic compounds are implicated in mediating the cancer-preventive actions of selenium. The mechanism proposed involves a reaction of this form of selenium with tumor-promoting lipid hydroperoxides bound to PKC; the resulting locally generated MSA inactivates PKC by oxidizing critical thiols present within the catalytic domain. The peroxidatic methylselenol-MSA redox cycle makes low nanomolar concentrations of selenium to catalytically oxidize sulfhydryl clusters in the proteins. While this occurs with the membrane-bound lipid hydroperoxides and proteins, this reaction occurs compartmentally separated from cytoplasmic GSH. It is astonishing that antitumor promoter selenium utilizes tumor promoting lipid hydroperoxides, restores cell death, and thereby prevents tumor promotion. The abundance of hydroperoxides in precancer cells makes them more susceptible to selenium-induced cytotoxicity than normal cells, where lipid hydroperoxides are less abundant. Third, we examine the reversal of selenometabolite-induced thiol oxidation of PKC isoenzymes by selenoprotein TR-containing system. This reversal mechanism is strongly supported by the presence of high affinity site for TRX on the catalytic domain of PKC. Another selenoprotein GPX may inhibit methylselenol-MSA redox cycle by removing hydroperoxides. Conceivably, in some cases selenoproteins can counteract the cytotoxicity induced by selenometabolites. This is especially important given that TR is overexpressed in advanced malignant cells, which may make them escape cancer-preventive actions of selenium. Finally, the relative susceptibility of antiapoptotic and proapoptotic en-
zymes to selenium-induced inactivation may explain
the intriguing U-shaped curve that is seen in the
dietary selenium intake and extent of cancer-prevention.
Selenium at lower concentrations oxidatively inactivates
antiapoptotic PKC isoenzymes (ε and α) hav-
ing both a lipid hydroperoxide-binding site and a
cluster of critical thiols in the catalytic domain.
However, at low concentrations selenium cannot in-
activate low affinity targets such as proapoptotic en-
zymes (PKC δ catalytic fragment, PKCζ, caspase-3,
and c-Jun N-terminal kinase) having a limited num-
ber of critical thiols. These spared proapoptotic en-
zymes induce apoptosis at lower concentrations of
selenium. On the other hand, tumor cells will be-
come resistant to apoptosis when these proapoptotic
enzymes are also inactivated by higher concentra-
tions of selenium.

Considering that ROS are generated in the action
of a variety of cancer-preventive agents, understand-
ing the cellular protein thiol redox status may help
optimize the cancer-preventive efficacy of not only selenium but also other chemopreventive agents.
Similarly, the imbalance in protein thiol oxidations
may contribute to selenium-induced clinical compli-
cations such as diabetes. Finally, the protein thiol
regulations may contribute to cell death in degenera-
tive diseases and thus this subject has broader impli-
cations beyond the realm of cancer prevention.

ACKNOWLEDGMENTS

The authors’ work was supported by grants from the
National Cancer Institute/National Institutes of
Health (CA099216) and the Swedish Cancer Society
(961).

REFERENCES

1. Combs GF, Jr., Gray WP. Chemopreventive
agents: selenium. Pharmacol Ther 1998;
2. Coates RJ, Weiss NS, Daling JR, Morris JS, Labbe
RF. Serum levels of selenium and retinol and the
3. Glattre E, Thomassen Y, Thoresen SO, Haldorsen
Prediagnostic serum selenium in a case-control
study of thyroid cancer. Int J Epidemiol 1989;
4. Milner JA. Effect of selenium on virally induced
and transplantable tumor models. Fed Proc 1985;
44(9):2568–72.
5. Ip C. Prophylaxis of mammary neoplasia by
selenium supplementation in the initiation and
promotion phases of chemical carcinogenesis.
6. el-Bayoumy K, Rao CV, Reddy BS. Multiorgan
sensitivity to anticarcinogenesis by the
organoselenium 1,4-
phenylenebis(methylene)selenocyanate. Nutr
Cancer 2001; 40(1):18–27. doi:
7. Dorado RD, Porta EA, Aquino TM. Effects of
dietary selenium on hepatic and renal
tumorigenesis induced in rats by
8. Perchellet JP, Abney NL, Thomas RM, Guislain
YL, Perchellet EM. Effects of combined treatments
with selenium, glutathione, and vitamin E on
 glutathione peroxidase activity, omithine
decarboxylase induction, and complete and
multistage carcinogenesis in mouse skin. Cancer
9. Li JY, Taylor PR, Li B, Dawsey S, Wang GQ,
Ershow AG, et al. Nutrition intervention trials in
Linxian, China: multiple vitamin/mineral
supplementation, cancer incidence, and disease-
specific mortality among adults with esophageal
10. Clark LC, Combs GF, Jr., Turnbull BW, Slate EH,
Chalker DK, Chow J, et al. Effects of selenium
supplementation for cancer prevention in patients
with carcinoma of the skin: a randomized
controlled trial. Nutritional Prevention of Cancer
11. Lippman SM, Klein EA, Goodman PJ, Lucia MS,
Thompson IM, Ford LG, et al. Effect of selenium
supplementation in the initiation and
decay phases of chemical carcinogenesis.
understanding success and failures in the use of
selenium for cancer prevention. Antioxid Redox
Signal 2013; 19(2):181–91. doi:
10.1089/ars.2013.5246.
13. Ganther HE, Corcoran C. Selenotrisulfides. II.
Cross-linking of reduced pancreatic ribonuclease
36. Gladyshev VN, Jeang KT, Stadtman TC. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human


55. Deagen JT, Butler JA, Zachara BA, Whanger PD. Determination of the distribution of selenium in rat liver is not affected by supranutritional levels of monomethylated selenium in vivo and is inhibited only by high levels of selenium in vitro. *J Nutr* 2001; 131(2):301–4.


81. Gopalakrishna R, Gundimeda U, Chen ZH. Cancer-preventive selenocompounds induce a specific redox modification of cysteine-rich regions in Cu²⁺-dependent isoenzymes of protein kinase C.
ROS


